The estrogen receptor α (ER α ), progesterone receptor (PR), and erbB2 (Her2 in humans) are important prognostic markers of human breast cancer, and they are variably expressed in different subtypes of breast cancer. The basal subtype, for example, is negative for ER α , PR, and Her2 by immunohistochemistry. We investigated the expression of these signaling molecules in enriched populations of mouse mammary stem cells and luminal cells that were isolated according to their differential expression of CD24 and the α 6 β 1-integrin complex. We found that the basal population, which is enriched in mouse mammary stem cells, did not express ER α , PR, or ErbB2/Her2 but did express epidermal growth factor receptor (EGFR)/ ErbB1, whereas the subset of cells enriched for luminal cells expressed ER α (37% of cells) and PR (40% of cells) but not ErbB2/Her2 or EGFR/ErbB1. Ovariectomy confi rmed the importance of estrogen signaling to luminal cell proliferation but had no effect on the size of the mouse mammary stem cell-enriched population. Thus, mouse mammary stem cells were negative for ER α , PR, and ErbB2 and appeared to share common properties with poorprognosis basal breast cancer. ( 1 , 2 ) . Estrogen receptor α (ER α ) is a critical element in the defi nition of the luminal A and B subclasses, with the luminal B subtype (which expresses lower levels of ER α transcripts) representing the more aggressive and less effectively treated subtype of the two.
Recent gene-profi ling studies have provided a basis for classifying human breast tumors into the following fi ve subtypes: luminal A, luminal B, ErbB2/ Her2, basal, and a normal breast-like subtype ( 1 , 2 ) . Estrogen receptor α (ER α ) is a critical element in the defi nition of the luminal A and B subclasses, with the luminal B subtype (which expresses lower levels of ER α transcripts) representing the more aggressive and less effectively treated subtype of the two. The basal subtype of breast cancer does not express the ER α , progesterone receptor (PR), or ErbB2/Her2 but generally does express cytokeratin 5 or 6 and epidermal growth factor receptor (EGFR)/ ErbB1 ( 3 ) . Basal cancers are associated with a poor prognosis and commonly develop in BRCA1 mutation carriers ( 4 , 5 ) . Such classifi cations have stimulated great interest in identifying the cells in which these phenotypically distinct tumor types arise. One possibility is that normal progenitors already restricted in their differentiation potential may be transformed directly by acquiring mutations that endow them with self-renewal properties (akin to stem cells). Other possibilities are that normal stem cells may be initially targeted and then additional genetic changes responsible for full malignancy arise in later progenitors or that all changes could be confi ned to stem cells but result in more profound effects in later cell types ( 6 , 7 ) . These possibilities prompted us to investigate the expression of ER α , PR, ErbB2/Her2, and EGFR/ErbB1 in normal mouse mammary stem cells.
We have recently described ( 8 , 9 ) methods for the prospective and differential isolation of enriched populations of mouse mammary stem cells and their derivative colony-forming cell progeny, the latter cells being in the luminal population. These isolation methods involve the removal of hematopoietic and endothelial cells and the selection of different mammary cell subsets by their surface expression level of CD24 (heat-stable antigen) and either component of the α 6 β 1-integrin complex (i.e., CD49f and CD29, respectively) ( Fig. 1, A and B ) . Mammary epithelial cells that express high levels of CD24 (CD24 + ) and lower levels of CD29 or CD49f (CD29 lo and CD49f lo , respectively) have features of luminal cells, as assessed by immunostaining and gene expression studies, and are enriched in mouse mammary stem cell derivative colony-forming cell progeny. Similar studies of cells expressing slightly lower levels of CD24 (termed CD24 + in this report) and the highest levels of CD29 or CD49f (CD29 hi and CD49f hi , respectively) indicate that these express markers of the basally located myoepithelial cells and are highly enriched in their content of mouse mammary stem cells.
We determined the expression of ER α in the mouse mammary stem cellenriched and luminal cell populations at the mRNA and protein levels. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analyses of RNA extracts from the two populations defi ned by CD49f and CD24 showed that ER α transcripts were confi ned to the luminal population ( Fig. 1, A ) . Consistent with these fi ndings, immunostaining of double-sorted CD24 + cells distinguished by their expression of CD29 ( Fig. 1, B ) confi rmed that a substantial proportion (37%, 95% confi dence interval [CI] = 23% to 51%) of the luminal CD29 lo cells express ER α protein, whereas the mouse mammary stem cell-enriched populations do not (less than 0.01%) ( Fig. 1 , C and D ). We therefore conclude that mouse mammary stem cells are ER α negative.
We then evaluated these same subpopulations for their expression of other markers of important prognostic significance in breast cancer ( 10 ) , including the PR, the tyrosine kinase receptors ErbB2/ Her2 and EGFR/ErbB1, the cell cycle inhibitors p21 and p27, and the proliferation marker proliferating cell nuclear antigen (PCNA). Very few cells in the mouse mammary stem cell-enriched population (less than 0.01%) expressed detectable levels of PR, as compared with the luminal population (40%, 95% CI = 24% to 55%), similar to that observed for ER α ( Fig. 1, C and D ) . In addition, few cells in the mouse mammary stem cell-enriched population expressed p21 (2%, 95% CI = 1.8% to 2.6%). In contrast, a substantial proportion of this subpopulation expressed PCNA (21%, 95% CI = 15% to 27%), EGFR/ErbB1 (49%, 95% CI = 37% to 61%) and p27 (39%, 95% CI = 36% to 43%), as well as several expected markers of myoepithelial cells (p63 and keratin 14; 63%, 95% CI = 58% to 67%, and 95%, 95% CI = 93% to 96%, respectively) but not keratin 18, a feature of luminal cells. In contrast, the ER α -positive, keratin 18-positive luminal cell population contained a high proportion of cells that were positive for p21 (67%, 95% CI = 50% to 83%) and p27 (60%, 95% CI = 58% to 62%), with 20% (95% CI = 10% to 31%) positive for PCNA and considerably fewer cells that expressed the basal markers. The high association between the expression of ER α , p21, and 
cytometric expression profi le of CD24 and CD49f (heat-stable antigen and α 6-integrin, respectively) in mammary cells depleted of hematopoietic and endothelial cells from C57BL/6 mice showing the populations of isolated luminal (LUM; CD49f lo CD24 + ) and MaSCenriched (CD49f hi CD24 + ) cell subsets, as assessed by the relative intensity of staining as previously described ( 9 ) . Right ) Relative levels of ER α mRNA in these subpopulations, measured by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) ( n = 3 experiments), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the endog enous reference used to normalize the levels of RNA. The 5 ′ to 3 ′ sequences of the primer pairs used were as follows: GAPDH forward, 5 ′ -CCCATCAC CATCTTCCAGGAG
was used to isolate luminal (CD-29 lo CD24 + ) and MaSC-enriched (CD29 hi CD24 + ) cell subsets as previously described is shown ( 8 ) . C ) Representative immunostaining of ER α , progesterone receptor (PR, A isoform), ErbB2/Her2, epidermal growth factor receptor (EGFR)/ErbB1, the p53 family member p63, and the cell cycle inhibitor p21 in the doubly sorted subpopulations shown in panel B. ER α inset ) Isotype control. ErbB2 inset ) Positive control cells from a mammary tumor arising in a mouse mammary tumor virus-neu (ErbB2) transgenic mouse. Real-time RT-PCR confi rmed low levels of ErbB2 transcript in the two populations (data not shown). Freshly sorted cells were cytospun onto a slide, fi xed with 4% paraformaldehyde at room temperature for 10 minutes, and then stained with the following antibodies: ER α (Santa Cruz, Richmond, CA), PR (hPRa7, a gift from C. Clarke, Westmead Millennium Institute, Westmead, New South Wales, Australia) ( 18 ) , ErbB2 (Calbiochem, Darmstadt, Germany), EGFR (Cell Signalling, Beverly, MA), p63 (BD Pharmingen, Bedford, MA), cytokeratin (K) 14 (Covance, Berkeley, CA), K18 (Progen Biotechnik, Heidelberg, Germany), p21 (Santa Cruz), p27 (Santa Cruz), or proliferating cell nuclear antigen (PCNA) (DAKO, Glostrup, Denmark). Slides were then incubated with either biotinylated goat anti-rabbit or goat anti-mouse immunoglobulin G (Vector, Burlingame, CA). A streptavidin-biotin peroxidase detection system was used with 3,3 ′ -diaminobenzidine as substrate (DAKO). Positive reaction gives a brown staining. Scale bars = 25 μ m. D ) Histograms showing the mean percentages ( error bars as 95% confi dence intervals) of positively stained cells, with the indicated antibodies, in the luminal (CD29 lo ) and MaSC-enriched (CD29 hi ) CD24 + populations shown in panel B, as well as for K14, K18, p27, and PCNA. Mammary cell suspensions were prepared from six to eight female FVB/NJ mice (8 to 10 weeks old) for each experiment. A minimum of 1000 cells in 10 randomly selected fi elds was counted under a ×40 objective, with each fi eld containing approximately 100 cells. Data are from two (ErbB2, EGFR, p63, K14, K18, p21, p27, and PCNA staining) or three (ER and PR staining) experiments. The paired t test value comparing the CD29 lo CD24 + (luminal) and CD29 hi CD24 + (MaSC-enriched) populations for each marker was used to determine statistical signifi cance as follows: ER α , P = .01; PR, P = .01; EGFR, P = .04; p63, P = .04; K14, P = .06; K18, P = .003; p21, P = .04; p27, P = .08. None of 1000 cells were ER α or PR positive in the CD29 hi CD24 + population.
p27 and the luminal cell population is consistent with data that ER α -positive cells in the mammary gland are noncycling ( 11 ) . The presence of some PCNA-positive cells in both populations is consistent with previous fi ndings indicating that both mouse mammary stem cells and their derivative colony-forming cell progeny are proliferating in vivo ( 9 ) . ErbB2/Her2 staining was negligible in both cell populations, in contrast to the high levels in mammary tu mor cells from ErbB2 transgenic mice ( Fig. 1, C , inset) . This fi nding is consistent with previous reports of low levels of ErbB2/Her2 in rodent ( 12 , 13 ) and hu man ( 14 ) mammary epithelium, as as sessed by immunohistochemistry. Thus, the mouse mammary stem cell-enriched subpopulation has an ER α -negative, PR-negative, and ErbB2/ Her2-negative phenotype and expresses abundant p63, cytokeratin 14, and EGFR, all of which are hallmarks of the basal subclass of human breast cancers ( 3 , 15 ) .
To determine the functional consequences of estrogen signaling on mammary cell subpopulations, we performed bilateral ovariectomies on adult (8-weekold) virgin female mice and then analyzed the number of CD29 lo CD24 + (luminal) cells and CD29 hi CD24 + (basal or myoepithelial) cells present in their mammary glands 3 weeks later. Ovariectomy produced a marked and selective reduction in the number of CD29 lo CD24 + (luminal) cells, as compared with age-matched nonovariectomized control mice ( Fig. 2 ) , but the number of CD29 hi CD24 + (basal or myoepithelial) cells remained unchanged. Thus, consistent with their steroid hormone receptor phenotype (ER α + , PR + ), the size of the luminal population was highly sensitive to hormonal deprivation, in contrast to the ER α − , PR − mouse mammary stem cell-enriched population, which was unaffected by hormonal deprivation.
The phenotype of the mouse mammary stem cell-enriched population thus recapitulates numerous characteristics of the basal phenotype of human breast cancer. However, ovariectomy affords some protection against breast tumorigenesis in BRCA1 mutation carriers ( 16 , 17 ) , although in our study, we detected no effect of ovariectomy on the size of the basal population, which is highly enriched in mouse mammary stem cells. Our study is potentially limited by the lack of known markers that would further enrich for mammary stem cells or provide a better defi nition of the progenitor cells that they generate. Markers that identify human breast stem cells are also currently not known, and it is possible that there will be species-specifi c differences. However, the key signaling molecules that we have described are shared between mice and humans. Additional experiments will therefore be required to determine how ovariectomy may have this differential effect. One possibility is that paracrine signaling from adjacent ER α -positive luminal cells infl uences stem cell behavior. Alternatively, further delineation of the hierarchy of stem and progenitor cells within the mammary gland may reveal as yet unidentifi ed intermediates with basal-like features but with biologically relevant levels of ER and PR expression. 
